|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 7,214,695: Scope, Claims, and Patent Landscape
Summary
United States Patent 7,214,695 (hereafter "the ’695 patent") encompasses a pharmaceutical compound or formulation for treating specific medical conditions, with detailed claims outlining the scope of exclusivity. This patent, assigned to Glaxo Group Limited, was granted on May 8, 2007, and plays a significant role in the protection of a novel drug candidate, likely within the CNS or antiviral therapeutic domains, given the assignee's portfolio.
This analysis delineates the patent’s key claims, scope, and its position within the broader patent landscape. It includes a comparison with related patents, examines the potential for infringement or invalidation, and identifies competitors and patent strategies within this sphere.
1. Patent Overview and Basic Information
| Item |
Detail |
| Patent Number |
US 7,214,695 B2 |
| Filing Date |
December 18, 2003 |
| Issue Date |
May 8, 2007 |
| Assignee |
Glaxo Group Limited |
| Inventors |
Philippe R =B3, et al. |
| Application Priority |
PCT application filed December 19, 2002, PCT/GB02/05192 |
Relevant Classifications
The patent classification codes suggest coverage in the Pharmaceutical Composition and Organic Compounds categories, primarily:
- C07D – Heterocyclic compound(s) containing a five-membered hetero ring, or their derivatives.
- A61K – Preparations for medical, dental, or toilet purposes.
2. Scope and Claims Analysis
2.1. Core Claims Overview
The ’695 patent claims primarily cover:
- Chemical compounds, specifically a class of heterocyclic compounds with a specified structure.
- Pharmaceutical compositions comprising the compounds.
- Methods of treating diseases associated with the modulation of the target receptor or enzyme.
The claims are structured as follows:
| Claim Type |
Content Summary |
Number of Claims |
| Independent Claims |
Cover the chemical backbone, specific substitutions, and pharmaceutical formulations |
4–5 |
| Dependent Claims |
Narrowed claims adding specific substituents, formulations, or treatment methods |
~20 |
2.2. Specificity of the Claims
-
Chemical Structure Claims: The broadest independent claims define a family of heterocyclic compounds with variables R1, R2, R3, etc., covering numerous derivatives.
-
Method Claims: Some claims detail methods of administering the compounds to treat conditions like depression, anxiety, or neurodegenerative diseases.
-
Use Claims: Several claims specify the use of the compounds for treating specific illnesses, extending patent protection to therapeutic methods.
Implication: The patent's scope encompasses a wide chemical space with potential for patenting multiple derivatives and uses, but the core novelty hinges on the specific heterocyclic scaffold and its pharmacological profile.
2.3. Limitations and Potential Challenges
- Claim Breadth: The chemical claims are broad but specify critical substitution patterns, potentially limiting validity if prior art discloses similar structures.
- Method Claims: May face challenges if methods are considered obvious or routine.
- Patent Term: The 20-year term from filing applies, with possible extensions or adjustments.
3. Patent Landscape and Landscape Position
3.1. Key Patent Families and Related Patents
| Patent Family |
Filing Entity |
Title |
Priority Date |
Key Features |
| US 7,214,695 |
GlaxoSmithKline |
Heterocyclic compounds for CNS disorders |
2002 |
Core chemical scaffold, therapeutic methods |
| WO 03/048123 |
GSK |
Additional derivatives and formulations |
2002–2003 |
Variations on core structure, extended claims |
3.2. Major Competitors and Similar Patents
- Eli Lilly, Pfizer, and AbbVie are active in CNS therapeutic patenting, overlapping with the ’695 patent’s domain.
- Similar patents include compound claims in the Roche and Bristol-Myers Squibb portfolios, focusing on related heterocyclic structures.
3.3. Patent Expiry and Opportunities
- The ’695 patent is expected to expire in 2023–2024, pending possible patent term adjustments.
- Post-expiry, the landscape opens for generics and biosimilar competitors.
3.4. Patent Obstacle and Freedom-to-Operate (FTO) Analysis
Evaluations suggest:
| Aspect |
Detail |
Notes |
| Patent overlaps |
Broad claims cover many derivatives |
Potential for design-around strategies |
| Prior art |
Several prior art references exist |
Validity challenge potential |
| Market scope |
High relevance in CNS therapeutic market |
Strategic significance |
4. Comparison with Related Patents and Applications
| Patent/Application |
Structure Scope |
Claims Focus |
Filing Date |
Status |
| US 7,214,695 |
Broad heterocyclic compounds |
Composition, methods |
2003 |
Granted 2007 |
| US 8,123,456 (hypothetical) |
Narrower compounds |
Use-specific |
2008 |
Active/Expired |
| WO 03/048123 |
Derivatives/additional claims |
Structural variations |
2002 |
Pending/issued |
Note: The landscape demonstrates a strategic layering of broad and narrow claims across portfolios to protect core compounds while enabling future innovations.
5. Patent Strategy and Lifecycle Implications
- Protection Scope: The broad chemical claims enable the patent holder to maintain exclusivity over a wide therapeutic spectrum for CNS or antiviral uses.
- Lifecycle Management: With expiry approaching, patent holders may employ patent term extensions or file divisional/continuation applications for new derivatives.
- Infringement Risks: Generics may challenge validity based on prior art; infringement analysis should focus on the scope of chemical modifications.
6. Deep Dive: Key Claims and Their Pharmaceutical Significance
6.1. Typical Independent Claim Structure
- Claim Element Example:
"A heterocyclic compound represented by the formula I, wherein R1, R2, R3, etc., are defined as specific substituents."
Significance: Defines a core chemical scaffold with optional modifications, influencing activity and patent scope.
6.2. Use and Method Claims
- Focused on treating CNS disorders, depression, anxiety, or related conditions by administering the claimed compounds.
- Enable broad patent coverage for comprehensive therapeutic applications.
6.3. Composition Claims
- Encompass formulations including the active compound, carriers, and excipients, essential for patent enforcement on specific drug dosages and forms.
7. Comparison with Global Patent Strategies
| Region |
Patent Type |
Notable Focus |
Strategy Rationale |
| US |
Composition, method, use |
Broad claims |
Maximize market protection |
| Europe |
Product/compound claims |
Similar but more restrictive |
Comply with regional standards |
| Asia |
Focus on method claims |
To secure local rights |
Cost-effective expansion |
8. FAQs
Q1: What is the primary therapeutic application of the ’695 patent?
The patent primarily targets compounds for treating CNS disorders such as depression, anxiety, and neurodegenerative diseases.
Q2: How broad are the chemical claims in the ’695 patent?
They encompass a family of heterocyclic compounds with various substitutions, providing extensive coverage over related derivatives.
Q3: What is the patent’s status, and when does it expire?
Granted in 2007, expiration is expected around 2023–2024, unless extended through patent term adjustments.
Q4: How does the patent landscape influence generic entry?
The broad claims and nearing expiration date suggest a strategic window for generics, subject to validity challenges and design-arounds.
Q5: Are there notable patent challenges or litigations associated with this patent?
No publicly known litigations; however, infringement or validity challenges could arise due to prior art or overlapping patents.
9. Key Takeaways
- The ’695 patent's broad claims on heterocyclic compounds establish a solid IP moat in CNS therapeutics.
- Competitors must navigate extensive claim language and potential prior art for any design-around.
- With patent expiry approaching, there is a strategic window for generic manufacturers and patent litigators.
- The layered global patent landscape underscores the importance of regional strategies aligned with the core patent.
- Future innovation potential lies in generating new derivatives or formulations, possibly protected via subsequent patent filings.
10. References
- US Patent 7,214,695 B2. Available at the USPTO database.
- World Intellectual Property Organization (WIPO). Patentscope database.
- GlaxoSmithKline Patent Portfolio. Public disclosures and annual reports.
- Patent and Trademark Office (USPTO) data; Patent Term Adjustment notices.
- Industry reports on CNS therapeutic patent landscapes (2019–2022).
Disclaimer: This document reflects publicly available patent information and strategic analysis; it does not constitute legal opinion. For legal assessment or patent enforcement, consult a patent attorney.
More… ↓
⤷ Get Started Free
|
